American Association for Cancer Research
Browse
crc-23-0087-s05.pdf (39.83 kB)

Supplementary Fig. S5 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma

Download (39.83 kB)
journal contribution
posted on 2023-09-15, 14:20 authored by Shinya Sato, Masatoshi Nakagawa, Takeshi Terashima, Soichiro Morinaga, Yohei Miyagi, Eisaku Yoshida, Toru Yoshimura, Motoharu Seiki, Shuichi Kaneko, Makoto Ueno, Taro Yamashita, Naohiko Koshikawa

Comparison for the positive and negative ratios of CA19-9 and/or EphA2-NF in early-stage and late-stage PCs.

Funding

Abbott Laboratories (Abbott)

Japan Agency for Medical Research and Development (AMED)

MEXT | Japan Society for the Promotion of Science (JSPS)

Princess Takamatsu Cancer Research Fund

History

ARTICLE ABSTRACT

EphA2 N-terminus deletion is involved in pancreatic ductal carcinoma development from high-risk IPMN and EphA2-NF produced by cleavage can be used as a serum biomarker to diagnose pancreatic ductal carcinoma and predict pancreatic ductal carcinoma development from high-risk IPMN.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC